非小细胞肺癌根治性放疗联合或不联合度伐利尤单抗巩固治疗后低剂量照射区间质性肺病播散的临床特征与危险因素
该回顾性研究分析了2016年7月至2020年7月在本院接受根治性放疗的74例非小细胞肺癌患者的临床记录、CT影像和放疗计划数据,评估1年内复发及间质性肺病/放射性肺炎发生的危险因素。结果显示,度伐利尤单抗≥7个周期显著改善1年无进展生存(p<0.001),且度伐利尤单抗给药与≥2级间质性肺病/放射性肺炎无显著相关性;高HbA1c水平与间质性肺病/放射性肺炎在高剂量区外播散的模式显著相关(HR 1.842,95%CI 1.35-2.51)。
要点
- 度伐利尤单抗≥7个周期显著改善1年无进展生存(p<0.001)。
- 19例(26%)发生≥2级、7例(9.5%)发生≥3级间质性肺病/放射性肺炎。
- 12例(16%)出现高剂量(>40 Gy)区外播散,其中8例(67%)≥2级、3例(25%)为3级症状。
核心结论
- 根治性放疗联合或不联合度伐利尤单抗后,度伐利尤单抗改善1年无进展生存且未增加间质性肺病/放射性肺炎风险。
- 糖尿病因素与间质性肺病/放射性肺炎在较低剂量区或放疗野外播散的模式相关,且症状发生率较高。
- 作者认为需要进一步研究包括糖尿病在内的患者临床背景,以在放化疗后安全增加度伐利尤单抗的给药次数。
研究设计与样本
- 回顾性分析2016年7月至2020年7月在本院接受根治性放疗的74例非小细胞肺癌患者的临床记录、CT影像和放疗计划数据。
- 评估1年内复发及间质性肺病/放射性肺炎发生的危险因素。
- 采用Kaplan-Meier法分析生存,采用未校正和多变量Cox比例风险模型(校正V20,即接受≥20 Gy的肺体积比例)分析危险因素。
主要发现
- Kaplan-Meier法显示度伐利尤单抗≥7个周期显著改善1年无进展生存(p<0.001)。
- 完成放疗后19例(26%)诊断为≥2级、7例(9.5%)诊断为≥3级间质性肺病/放射性肺炎。
- 度伐利尤单抗给药与≥2级间质性肺病/放射性肺炎之间无显著相关性。
- 12例(16%)发生播散至高剂量(>40 Gy)区外的间质性肺病/放射性肺炎,其中8例(67%)有≥2级症状、3例(25%)有3级症状。
- 在未校正和多变量Cox比例风险模型(校正V20)中,高HbA1c水平与间质性肺病/放射性肺炎在高剂量区外播散的模式显著相关(风险比1.842;95%置信区间1.35-2.51)。
关键数值与推荐
- 度伐利尤单抗≥7个周期与1年无进展生存改善相关(p<0.001)。
- ≥2级间质性肺病/放射性肺炎19例(26%),≥3级7例(9.5%)。
- 高剂量(>40 Gy)区外播散的间质性肺病/放射性肺炎12例(16%),其中≥2级8例(67%)、3级3例(25%)。
- 高HbA1c水平与高剂量区外播散模式的HR为1.842(95%CI 1.35-2.51)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文为回顾性分析。
- 作者指出需要进一步研究包括糖尿病在内的患者临床背景,以在放化疗后安全增加度伐利尤单抗的给药次数。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The current standard of care for patients with unresectable locally advanced non-small cell lung cancer (NSCLC) is chemoradiotherapy (CRT) combined with durvalumab consolidation therapy. However, radiotherapy (RT) always carries the risk of radiation pneumonitis (RP), which can preclude durvalumab continuation. In particular, the spread of interstitial lung disease (ILD) in low-dose areas or extending beyond the RT field often makes it difficult to determine the safety of continuation or rechallenging of durvalumab. Thus, we retrospectively analyzed ILD/RP after definitive RT with and without durvalumab, with assessment of radiologic features and dose distribution in RT. METHODS: We retrospectively evaluated the clinical records, CT imaging, and radiotherapy planning data of 74 patients with NSCLC who underwent definitive RT at our institution between July 2016 and July 2020. We assessed the risk factors for recurrence within one year and occurrence of ILD/RP. RESULTS: Kaplan-Meier method showed that ≥ 7 cycles of durvalumab significantly improved 1-year progression free survival (PFS) (p < 0.001). Nineteen patients (26%) were diagnosed with ≥ Grade 2 and 7 (9.5%) with ≥ Grade 3 ILD/RP after completing RT. There was no significant correlation between durvalumab administration and ≥ Grade 2 ILD/RP. Twelve patients (16%) developed ILD/RP that spread outside the high-dose (> 40 Gy) area, of whom 8 (67%) had ≥ Grade 2 and 3 (25%) had Grade 3 symptoms. In unadjusted and multivariate Cox proportional-hazards models adjusted for V20 (proportion of the lung volume receiving ≥ 20 Gy), high HbA1c level was significantly correlated with ILD/RP pattern spreading outside the high-dose area (hazard ratio, 1.842; 95% confidence interval, 1.35-2.51). CONCLUSIONS: Durvalumab improved 1-year PFS without increasing the risk of ILD/RP. Diabetic factors were associated with ILD/RP distribution pattern spreading in the lower dose area or outside RT fields, with a high rate of symptoms. Further study of the clinical background of patients including diabetes is needed to safely increase the number of durvalumab doses after CRT.
引用
- Sakagami M, Inokuchi H, Mukumoto N, et al. Clinical features and risk factors for interstitial lung disease spreading in low-dose irradiated areas after definitive radiotherapy with or without durvalumab consolidation therapy for patients with non-small cell lung cancer. Radiat Oncol. 2023. PMID: 37217919. doi:10.1186/s13014-023-02276-7
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。